The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Theolytics appoints new Chief Medical Officer

08 Oct 2025

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in... Read more

Sitryx receives FDA clearance to progress trials of oral treatment of atopic dermatitis

03 Oct 2025

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for SYX-5219, to support the initiation of a Phase 1b trial in adults with moderate to severe atopic dermatitis in the United States. The Company expects to... Read more

Tres Alchemix raises $4.4M in Series A funding to accelerate AI-driven drug discovery

26 Sep 2025

Tres Alchemix, an early-stage biotechnology company applying artificial intelligence (AI) to drug discovery, today announced it has closed a $4.4 million Series A financing. The round was led by DNX Ventures, with participation from existing investor Waseda University Ventures. The funding will accelerate development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of... Read more

Moa and Nufarm announce next phase for their novel mode of action herbicide

22 Sep 2025

Moa Technology and Nufarm have announced the start of the next phase of their collaboration to bring an exciting novel mode of action agricultural herbicide to the global market, reaching this stage over a year earlier than typical industry timelines. The two companies have together assessed several promising novel mode of action compounds identified by Moa’s GALAXY discovery platform. These have demonstrated strong and consistent efficacy... Read more

EIT’s Dr Lennard Lee secures UK AI supercomputing award for cancer vaccine research

18 Sep 2025

Dr Lennard Lee, Chief Medical Officer of the EIT Clinic at the Ellison Institute of Technology, has been awarded access to the UK’s most powerful AI supercomputer to accelerate cancer vaccine research. The project, “A foundation model for cancer vaccine design”, has been selected by the UK Government’s AI Research Resource (AIRR) programme, led by the Department for Science, Innovation and Technology (DSIT) and UK Research and Innovation... Read more

News